

32nd annual meeting of the
Belgian Society of Intensive Care Medicine
June 15, 2012

Nutrients, insulin and muscle wasting during critical illness

Sarah Derde



Introduction

- ▶ Critical illness: feeding-resistant hypercatabolism
 - ▶ Imbalance between protein synthesis and breakdown

Introduction

- ▶ Critical illness: feeding-resistant hypercatabolism
 - ▶ Imbalance between protein synthesis and breakdown
 - ▶ Skeletal muscle = main protein source

Introduction

- ▶ Critical illness: feeding-resistant hypercatabolism
 - ▶ Imbalance between protein synthesis and breakdown
 - ▶ Skeletal muscle = main protein source

Severe muscle weakness

Introduction

- ▶ Critical illness: feeding-resistant hypercatabolism
 - ▶ Imbalance between protein synthesis and breakdown
 - ▶ Skeletal muscle = main protein source

Severe muscle weakness

Introduction

- ▶ Critical illness: feeding-resistant hypercatabolism
 - ▶ Imbalance between protein synthesis and breakdown
 - ▶ Skeletal muscle = main protein source

Severe muscle weakness

Introduction

- ▶ Critical illness: feeding-resistant hypercatabolism
 - ▶ Imbalance between protein synthesis and breakdown
 - ▶ Skeletal muscle = main protein source

Severe muscle weakness

Introduction

- ▶ Critical illness: feeding-resistant hypercatabolism
 - ▶ Imbalance between protein synthesis and breakdown
 - ▶ Skeletal muscle = main protein source



Severe muscle weakness

- ❑ rehabilitation: delayed
- ❑ mortality risk ↗
- ❑ after hospital discharge: quality of life ↘

Muscle weakness


Myofibrillar protein



- ▶ Ubiquitin proteasome system

- ▶ Autophagy

Protein degradation pathways: Ubiquitin-proteasome system



Muscle wasting

↑ MuRF-1
↑ Atrogin-1


↑ Lysosomal system



Protein degradation pathways: Autophagy

Degradation of own cellular components within lysosomes

Elongation




removing damaged proteins
energy supply

+ accumulation toxic protein aggregates

Role of autophagy in muscle wasting?

- ▶ Excessive activation → could aggravate muscle wasting
- ▶ Impairment/inhibition → could evoke atrophy and myopathy
 - ➡ muscle fiber degeneration
 - ➡ muscle weakness
- ▶ Effect of autophagy during prolonged critical illness ?

Inhibitors of catabolism




❖ Insulin

- ▶ Insulin resistance

❖ Nutrients

- ▶ Dysfunctional gastro-intestinal tract
- ▶ Intravenous nutrition:

ineffective to safely counteract hypercatabolism



➡ promotes catabolism


General hypothesis

Intravenous nutrition, while maintaining normoglycemia,
safely counteracts muscle wasting during
prolonged critical illness



Objectives

- ▶ 1. Effect of strict blood glucose control with intensive insulin therapy on muscle wasting in fed critically ill patients
- ▶ 2. Efficacy in counteracting protein degradation and safety of intravenous nutritional interventions in an animal model
- ▶ Effect of fasting versus ↗ intravenous glucose load



- ▶ Impact of altering nutritional substrate composition




Hypothesis I

Muscle atrophy in fed critically ill patients
can be attenuated by intensive insulin therapy

Derde et al, Crit Care Med 2012, 40:79-89
Vanhorebeek et al, J Clin Endocrinol Metab 2011, 96:E633-E645

▶ Study I: Insulin therapy and muscle wasting





Patient population



▶ Study I: Insulin therapy and muscle wasting

-
- ▶ Muscle protein synthesis
 - ▶ Myofiber size and morphology
 - ▶ Muscle protein degradation

Synthesis of myofibrillary proteins




- Healthy control
- Conventional insulin therapy
- Intensive insulin therapy

* : $P \leq 0.05$ versus control


▶ Study I: Insulin therapy and muscle wasting

Myofiber size: fiber cross-sectional area

Vastus lateralis





Rectus abdominis



- Healthy control
- Critically ill :conventional insulin therapy
- - - Critically ill: intensive insulin therapy

▶ Study I: Insulin therapy and muscle wasting

Morphological analysis of skeletal muscle:



Rectus abdominis



<u>Inflammation and/or necrosis</u> (n, %)	Present	P-value
--	---------	---------

Control	0 (0)	0.09
CIT	20 (28)	
IIT	16 (32)	


<u>Presence of adipocytes</u> (n, %)		P-value
--------------------------------------	--	---------

Control	4 (36)	0.01
CIT	55 (76)	
IIT	30 (60)	

Myofiber degeneration



Myofibers with centralized nuclei




- Control
- Conventional insulin therapy
- Intensive insulin therapy

* : $p \leq 0.05$ versus control // (*) : $p \leq 0.1$ versus control // §: $p \leq 0.05$ sick versus control





► Study I: Insulin therapy and muscle wasting

Protein degradation: autophagy

Vacuolization ↑



Impaired autophagy




* : $p \leq 0.05$ versus control
§) : $p \leq 0.1$ sick versus control


Control
Conventional insulin therapy
Intensive insulin therapy

▶ Study I: Insulin therapy and muscle wasting

Protein degradation : Ubiquitin-proteasome system



20 S proteasome activity



- Healthy control
- Conventional insulin therapy
- Intensive insulin therapy

* : $p \leq 0.05$ versus control // (§): $P \leq 0.1$ sick versus control

► Protein degradation: results

Conclusions

	Prolonged critical illness
gene expression myofibrillary proteins	
myosin/actin ratio	↓
Myofiber size	↓
autophagy	↓
20S proteasome	↑

No effect of intensive insulin therapy

2. Efficacy to attenuate protein degradation and safety of intravenous nutrition in an animal model of prolonged critical illness



Hypothesis 1




Increasing the intravenous glucose load,
within the physiological range and while maintaining
normoglycemia, safely counteracts muscle catabolism

Derde et al, Crit Care Med 2010, 38:602-611

▶ Study 2: increasing the intravenous glucose load

Experimental setup 1







▶ Study 2: increasing the intravenous glucose load

-
- ▶ Safety evaluation: survival & organ function
 - ▶ Muscle protein degradation

▶ Study 2: increasing the intravenous glucose load



Safety: Survival and organ function




§: $p < 0.05$ versus all other groups// * : $p < 0.05$ versus high/hg rabbits// #: $p < 0.05$ versus healthy control rabbits// : healthy reference range

▶ Study 2: increasing the intravenous glucose load




Muscle proteolysis

Weight loss



Urea






glucose load	(-)	Low	Moderate	High	High
glycemia		Normal			High
n	13	13	10	12	8

*: p < 0.05 versus high/hg rabbits // @: p < 0.05 versus moderate/ng rabbits // \$: p < 0.05 versus no/ng rabbits // #: p < 0.05 versus healthy control rabbits // +: p < 0.05 versus low/ng rabbits // : healthy reference range // §: p < 0.05 versus all other groups

▶ Study 2: increasing the intravenous glucose load

Muscle proteolysis: Ub-proteasome



glucose load	(-)	Low	Moderate	High	High
glycemia		Normal			High
n	13	13	10	12	8

*: $p < 0.05$ versus high/hg rabbits // @: $p < 0.05$ versus moderate/ng rabbits // \$: $p < 0.05$ versus no/ng rabbits // #: $p < 0.05$ versus healthy control rabbits // +: $p < 0.05$ versus low/ng rabbits // : healthy reference range

▶ Study 2: increasing the intravenous glucose load



Conclusion

- ▶ Increasing intravenous glucose load within physiological range while normoglycemia is maintained
 - ▶ Safe with regard to organ function and survival
 - ▶ Reduces biochemical markers of catabolism as compared with fasting
 - ▶ Optimum may be reached with moderate glucose intake
- ▶ High glucose load / hyperglycemia: ↓ protective effect nutrition

▶ Study 2: increasing the intravenous glucose load

Hypothesis 3




Impact of feeding on the catabolic pathways
may be nutrient-specific



Derde et al, Endocrinology. 2012 May;153(5):2267-76

▶ Study 3: altering substrate composition

Experimental setup 2



▶ Study 3: altering substrate composition

-
- ▶ Safety evaluation: survival & weight loss
 - ▶ Muscle fiber size: cross-sectional area
 - ▶ Muscle protein degradation
 - ▶ Ubiquitin proteasome pathway
 - ▶ autophagy









Safety: Survival and weight loss

- ▶ Survival: no mortality difference among groups
- ▶ Feeding attenuated weight loss observed in fasted critically ill rabbits

▶ Study 3: altering substrate composition

Muscle fiber size: cross-sectional area






cross sectional area (pixels²)

- fasted critically ill
- fed critically ill, extra glucose
- fed critically ill, extra lipids
- fed critically ill ,extra amino acids
- healthy reference range

▶ Study 3: altering substrate composition

Muscle proteolysis: Ub-proteasome







- fasted critically ill
- fed critically ill, extra glucose
- fed critically ill, extra lipids
- fed critically ill, extra amino acids
- healthy reference range

*: $p \leq 0.05$ versus healthy control rabbits; † $p \leq 0.05$ versus fasted critically ill rabbits; ‡ $p \leq 0.05$ versus critically ill rabbits from the glucose group

▶ Study 3: altering substrate composition



Muscle proteolysis: autophagy



*: $p \leq 0.05$ versus healthy control rabbits ; † $p \leq 0.05$ versus fasted critically ill rabbits; ‡ $p \leq 0.05$ versus critically ill rabbits from the glucose group



Conclusions

- ▶ Moderate amount of intravenous nutrition
 - ▶ Suppression atrophy at level of gene expression and activity
 - ▶ minor effect of nutrient composition: AA most effective?
 - ▶ reduced fiber size most preserved with extra AA
 - ▶ Suppression of autophagy
 - ▶ accumulation toxic protein aggregates /damaged organelles in skeletal muscle most pronounced with AA
 - ▶ Most anti-catabolic intervention (AA) may have been most toxic

▶ Study 3: altering substrate composition

General conclusion and perspectives

- ▶ Prevention of hyperglycemia in the fed condition is crucial to prevent ↗ mortality
- ▶ Intravenous nutrition while maintaining normoglycemia ↘ catabolism

BUT possible toxic side effects by inhibition autophagy!!
clinical setting ?

- ▶ Pharmacological intervention to stimulate autophagy
-



Acknowledgements

- ▶ Promoter: Prof. dr. G. Van den Berghe
- ▶ Co-promoter: Prof. dr. I. Vanhorebeek

- ▶ Prof. dr. V. Darras (Laboratory of Comparative Endocrinology, KUL)
- ▶ Prof. dr. L. Larsson (University Uppsala, Sweden)
- ▶ Prof. dr. W. Martinet (Universiteit Antwerpen)
- ▶ LEGENDO

- ▶ Excellent technical assistance: E. Ververs, I. Derese

- ▶ The colleagues of the Laboratory of Intensive Care Medicine



▶ This work was supported by :
The Fund for Scientific Research (FWO)
The Research Council of the Katholieke Universiteit Leuven
Long-term structural research financing via the Methusalem program

